Clinical comprehensive evaluation of Jinsang Liyan Pills/Capsules in treatment of chronic pharyngitis.
10.19540/j.cnki.cjcmm.20231009.501
- Author:
Tian-Tian ZHOU
1
;
Yan RUAN
2
;
Jing HU
1
;
Xing LIAO
3
Author Information
1. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University/Beijing Institute of Chinese Medicine/Beijing Evidence-based Chinese Medicine Center Beijing 100191, China.
2. the First Clinical Hospital of Guangzhou University of Traditional Chinese Medicine Guangzhou 510006, China.
3. Center for Evidence-based Medicine,Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
Jinsang Liyan Capsules;
Jinsang Liyan Pills;
chronic pharyngitis;
clinical comprehensive evaluation
- MeSH:
Humans;
Drugs, Chinese Herbal/therapeutic use*;
Pharyngitis/drug therapy*;
Medicine, East Asian Traditional;
Nonprescription Drugs/therapeutic use*;
Capsules
- From:
China Journal of Chinese Materia Medica
2023;48(23):6285-6293
- CountryChina
- Language:Chinese
-
Abstract:
According to the Guidelines for clinical comprehensive evaluation of Chinese patent medicine(2022 version), this study comprehensively compared the clinical value of Jinsang Liyan Pills/Capsules with that of another commonly used Chinese patent medicine(drug A).(1)Effectiveness: Jinsang Liyan Pills/Capsules had antimicrobial, anti-inflammatory, and pain-relieving effects and can improve the total response rate in the treatment of chronic pharyngitis. Moreover, they took effect faster than the control group.(2)Safety: Jinsang Liyan Pills/Capsules did not cause acute toxicity and long-term toxicity, with low incidence of adverse reactions, which were mild and alleviated after drug withdrawal. Therefore, the risk of Jinsang Liyan Pills/Capsules was under control.(3)Economy: Jinsang Liyan Pills/Capsules had lower cost per course of treatment than drug A. The incremental cost-effectiveness ratio(ICER) of Jinsang Liyan Pills combined with Jinsang Qingyin Pills was-39.97 yuan compared with conventional treatment. The ICER of Jinsang Liyan Pills compared with amoxicilin was 0.01 yuan. The results meant that Jinsang Liyan Pills/Capsules had a cost-effectiveness advantage.(4)Innovation: Jinsang Liyan Pills/Capsules had reasonably formula and wide indications, meeting the clinical needs. Moreover, they had been authorized four patents of advanced manufacturing technology.(5)Suitability: the storage and administration of Jinsang Liyan Pills/Capsules were convenient, with clear instruction of medication.(6) Accessibility: Jinsang Liyan Pills/Capsules had sufficient drug reserve, caused low economic burden of patients, and presented environmental bearing capacity. Finally, Jinsang Liyan Pills/Capsules were scored 79.10 points, and drug A 67.93 points. The experts reached the consensus of grade A for Jinsang Liyan Pills/Capsules, which can be directly converted into decision making. The result of this comprehensive evaluation of Jinsang Liyan Pills/Capsules highlight the clinical advantages in the treatment of chronic pharyngitis and lay a foundation for the standardized research on the clinical basic research of the drug in the future.
